Skip to main content

Table 3 Univariate and multivariate analyses of factors associated with overall survival

From: A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment

Variables

Univariate

Multivariate

HR

95%CI

p value

HR

95%CI

p value

Lower

Upper

Lower

Upper

ENZ vs ABI

1.280

0.873

1.884

0.205

1.105

0.810

1.507

0.529

Metastasis vs non-metastasis

1.200

0.835

1.719

0.328

1.412

1.011

1.970

0.043

Gleason score ≥ 8 vs Gleason score < 8

0.810

0.566

1.148

0.232

1.004

0.731

1.379

0.981

Age ≥ 75.6 (median) vs < 75.6

1.100

0.770

1.571

0.601

0.988

0.729

1.338

0.938

DOC treatment vs non-DOC treatment

2.070

1.410

3.045

< 0.001

2.160

1.571

2.970

< 0.001

NLR > 3.02 vs ≤3.02

2.070

1.094

2.300

0.015

2.115

1.540

2.906

< 0.001

ALP > 274 (median) vs ≤274

1.580

1.295

2.760

< 0.001

2.189

1.579

3.035

< 0.001

LDH > 220 (median) vs ≤220

1.790

1.234

2.597

0.002

2.284

1.647

3.168

< 0.001

  1. HR Hazard ratio, CI Confidential interval, ABI Abiraterone, ENZ Enzalutamide, DOC Docetaxel
  2. NLR Neutrophil to lymphocyte ratio, ALP Alkaline phosphatase, LDH Lactate dehydrogenas